Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies

Fred R. Hirsch; Keith M. Kerr; Paul A. Bunn; Edward S. Kim; Coleman Obasaju; Maurice Pérol; Philip Bonomi; Jeffrey D. Bradley; David Gandara; James R. Jett; Corey J. Langer; Ronald B. Natale; Silvia Novello; Luis Paz-Ares; Suresh S. Ramalingam; Martin Reck; Craig H. Reynolds; Egbert F. Smit; Mark A. Socinski; David R. Spigel; Thomas E. Stinchcombe; Johan F. Vansteenkiste; Heather Wakelee; Nick Thatcher

doi:10.1016/j.cllc.2018.03.014

Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies

Fred R. Hirsch, Keith M. Kerr, Paul A. Bunn, Edward S. Kim, Coleman Obasaju, Maurice Pérol, Philip Bonomi, Jeffrey D. Bradley, David Gandara, James R. Jett, Corey J. Langer, Ronald B. Natale, Silvia Novello, Luis Paz-Ares, Suresh S. Ramalingam, Martin Reck, Craig H. Reynolds, Egbert F. Smit, Mark A. Socinski, David R. SpigelThomas E. Stinchcombe, Johan F. Vansteenkiste, Heather Wakelee, Nick Thatcher

Research output: Contribution to journal › Review article › peer-review

15 Scopus citations

Abstract

Patients with non–small-cell lung cancer, including squamous-cell lung cancer (SqCLC), typically present at an advanced stage. The current treatment landscape, which includes chemotherapy, radiotherapy, surgery, immunotherapy, and targeted agents, is rapidly evolving, including for patients with SqCLC. Prompt molecular and immune biomarker testing can serve to guide optimal treatment choices, and immune biomarker testing is becoming more important for this patient population. In this review we provide an overview of current and emerging practices and technologies for molecular and immune biomarker testing in advanced non–small-cell lung cancer, with a focus on SqCLC.

Original language	English
Pages (from-to)	331-339
Number of pages	9
Journal	Clinical Lung Cancer
Volume	19
Issue number	4
DOIs	https://doi.org/10.1016/j.cllc.2018.03.014
State	Published - Jul 2018

Keywords

Immune-oncology
Molecular testing
Non–small-cell lung cancer
PD-L1
Pathology
Targeted treatment

Access to Document

10.1016/j.cllc.2018.03.014

Cite this

Hirsch, F. R., Kerr, K. M., Bunn, P. A., Kim, E. S., Obasaju, C., Pérol, M., Bonomi, P., Bradley, J. D., Gandara, D., Jett, J. R., Langer, C. J., Natale, R. B., Novello, S., Paz-Ares, L., Ramalingam, S. S., Reck, M., Reynolds, C. H., Smit, E. F., Socinski, M. A., ... Thatcher, N. (2018). Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies. Clinical Lung Cancer, 19(4), 331-339. https://doi.org/10.1016/j.cllc.2018.03.014

@article{0e1131efff9c4be7a5e3f225b99b80de,

title = "Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies",

abstract = "Patients with non–small-cell lung cancer, including squamous-cell lung cancer (SqCLC), typically present at an advanced stage. The current treatment landscape, which includes chemotherapy, radiotherapy, surgery, immunotherapy, and targeted agents, is rapidly evolving, including for patients with SqCLC. Prompt molecular and immune biomarker testing can serve to guide optimal treatment choices, and immune biomarker testing is becoming more important for this patient population. In this review we provide an overview of current and emerging practices and technologies for molecular and immune biomarker testing in advanced non–small-cell lung cancer, with a focus on SqCLC.",

keywords = "Immune-oncology, Molecular testing, Non–small-cell lung cancer, PD-L1, Pathology, Targeted treatment",

author = "Hirsch, {Fred R.} and Kerr, {Keith M.} and Bunn, {Paul A.} and Kim, {Edward S.} and Coleman Obasaju and Maurice P{\'e}rol and Philip Bonomi and Bradley, {Jeffrey D.} and David Gandara and Jett, {James R.} and Langer, {Corey J.} and Natale, {Ronald B.} and Silvia Novello and Luis Paz-Ares and Ramalingam, {Suresh S.} and Martin Reck and Reynolds, {Craig H.} and Smit, {Egbert F.} and Socinski, {Mark A.} and Spigel, {David R.} and Stinchcombe, {Thomas E.} and Vansteenkiste, {Johan F.} and Heather Wakelee and Nick Thatcher",

note = "Publisher Copyright: {\textcopyright} 2018 The Authors",

year = "2018",

month = jul,

doi = "10.1016/j.cllc.2018.03.014",

language = "English",

volume = "19",

pages = "331--339",

journal = "Clinical Lung Cancer",

issn = "1525-7304",

number = "4",

}

Hirsch, FR, Kerr, KM, Bunn, PA, Kim, ES, Obasaju, C, Pérol, M, Bonomi, P, Bradley, JD, Gandara, D, Jett, JR, Langer, CJ, Natale, RB, Novello, S, Paz-Ares, L, Ramalingam, SS, Reck, M, Reynolds, CH, Smit, EF, Socinski, MA, Spigel, DR, Stinchcombe, TE, Vansteenkiste, JF, Wakelee, H & Thatcher, N 2018, 'Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies', Clinical Lung Cancer, vol. 19, no. 4, pp. 331-339. https://doi.org/10.1016/j.cllc.2018.03.014

TY - JOUR

T1 - Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer

T2 - Effect of Current and Future Therapies and Technologies

AU - Hirsch, Fred R.

AU - Kerr, Keith M.

AU - Bunn, Paul A.

AU - Kim, Edward S.

AU - Obasaju, Coleman

AU - Pérol, Maurice

AU - Bonomi, Philip

AU - Bradley, Jeffrey D.

AU - Gandara, David

AU - Jett, James R.

AU - Langer, Corey J.

AU - Natale, Ronald B.

AU - Novello, Silvia

AU - Paz-Ares, Luis

AU - Ramalingam, Suresh S.

AU - Reck, Martin

AU - Reynolds, Craig H.

AU - Smit, Egbert F.

AU - Socinski, Mark A.

AU - Spigel, David R.

AU - Stinchcombe, Thomas E.

AU - Vansteenkiste, Johan F.

AU - Wakelee, Heather

AU - Thatcher, Nick

PY - 2018/7

Y1 - 2018/7

N2 - Patients with non–small-cell lung cancer, including squamous-cell lung cancer (SqCLC), typically present at an advanced stage. The current treatment landscape, which includes chemotherapy, radiotherapy, surgery, immunotherapy, and targeted agents, is rapidly evolving, including for patients with SqCLC. Prompt molecular and immune biomarker testing can serve to guide optimal treatment choices, and immune biomarker testing is becoming more important for this patient population. In this review we provide an overview of current and emerging practices and technologies for molecular and immune biomarker testing in advanced non–small-cell lung cancer, with a focus on SqCLC.

AB - Patients with non–small-cell lung cancer, including squamous-cell lung cancer (SqCLC), typically present at an advanced stage. The current treatment landscape, which includes chemotherapy, radiotherapy, surgery, immunotherapy, and targeted agents, is rapidly evolving, including for patients with SqCLC. Prompt molecular and immune biomarker testing can serve to guide optimal treatment choices, and immune biomarker testing is becoming more important for this patient population. In this review we provide an overview of current and emerging practices and technologies for molecular and immune biomarker testing in advanced non–small-cell lung cancer, with a focus on SqCLC.

KW - Immune-oncology

KW - Molecular testing

KW - Non–small-cell lung cancer

KW - PD-L1

KW - Pathology

KW - Targeted treatment

UR - http://www.scopus.com/inward/record.url?scp=85047199857&partnerID=8YFLogxK

U2 - 10.1016/j.cllc.2018.03.014

DO - 10.1016/j.cllc.2018.03.014

M3 - Review article

C2 - 29773328

AN - SCOPUS:85047199857

SN - 1525-7304

VL - 19

SP - 331

EP - 339

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

IS - 4

ER -

Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this